Alan Brochstein, CFA, is one of the first investment professionals to focus exclusively on the cannabis industry. Alan got his start as a financial professional in the securities industry in 1986, managing investments in institutional environments until he founded AB Analytical Services in 2007 in order to provide independent consulting to registered investment advisors. He is also the managing partner of New Cannabis Ventures, a leading provider of relevant financial information in the cannabis industry si ...

Financial Data and Key Metrics Changes - The company reported a net revenue increase of 17% to $42.7 million compared to Q1 of the previous year, driven by growth in flagship brands SHRED and BOXHOT [32][34] - Adjusted gross margin increased to $14.3 million or 33%, up from 31% in the prior year, attributed to increased international sales and operational efficiencies [34] - The net loss for the quarter was $23 million compared to a net loss of $15.8 million in Q1 fiscal 2024, with adjustments indicating a net loss of $4.1 million when excluding fair value losses [40][41] Business Line Data and Key Metrics Changes - The recreational business grew by 15%, with significant contributions from both core and newly acquired product lines [32][33] - The company expanded its national market share by 500 basis points year-over-year, with notable growth in vapes and pre-rolls, where it achieved the number one position [11][12] - Supporting brands like Big Bag O' Buds and Debunk saw impressive growth, doubling their market share compared to Q1 last year [10][11] Market Data and Key Metrics Changes - The Canadian cannabis industry grew by 7.7% year-over-year in Q1, driven by strong demand in pre-rolls and vapes [11] - International sales reached $3.3 million, reflecting a 2.3 times year-over-year increase [34] - The company anticipates continued growth in international sales throughout fiscal 2025, supported by strategic investments and partnerships [30] Company Strategy and Development Direction - The integration of the Motif acquisition is a key focus, with expected operational synergies of $10 million over 24 months [22][38] - The company is investing in seed-based cultivation to enhance efficiency and reduce costs, with plans to increase flower output significantly [20][25] - International expansion remains a priority, particularly in the German market, with a $21 million investment in Sanity Group to capitalize on growth opportunities [28][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving operational efficiencies and market position improvements, anticipating a stabilization of adjusted gross margin around 35% in fiscal 2025 [35][44] - The company is optimistic about the international market growth, particularly in Germany, and plans to leverage its EU GMP certification to enhance margins [29][72] - Management highlighted the potential for favorable changes in government policy regarding cannabis regulation and taxation, which could benefit the industry [76][81] Other Important Information - The company plans to invest $8 million to $10 million in sustaining capital expenditures during fiscal 2025, alongside an additional $16 million for capacity enhancement projects [42] - Cash position as of December 31 was $71.2 million, with negligible debt, indicating a strong balance sheet [41][43] Q&A Session Summary Question: Insights on international market growth and investment opportunities - Management highlighted the growth of the German medical market and the potential for increased demand through strategic partnerships, particularly with Sanity Group [51][72] Question: Pro-forma financials and profitability trends - Management indicated that consolidated EBITDA is expected to exceed last year's figures, with significant synergies anticipated in the back half of the year [61][62] Question: Strength of international markets and EU GMP certification timing - Management noted that the EU GMP certification will enhance margins and demand, despite increased competition in the international market [70][72] Question: Potential impacts of government changes on the cannabis industry - Management discussed the potential for favorable regulatory changes under a new government, which could support industry growth and reduce excise taxes [76][81]

OrganiGram (OGI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -66.67%. A quarter ago, it was expected that this cannabis producer would post a loss of $0.03 per share when it actually produced a loss of $0.04, delivering a surprise of -33.33%.Over the last four quarters, the company has su ...

INTRODUCTION This Management's Discussion and Analysis dated February 11, 2025 (this "MD&A"), should be read in conjunction with the unaudited condensed consolidated interim financial statements (the "Interim Financial Statements") of Organigram Holdings Inc. (together with its subsidiaries, the "Company", "Organigram", "we", "us", or "our") for the three months ended December 31, 2024 ("Q1 Fiscal 2025"), and the audited annual consolidated financial statements for the year ended September 30, 2024 ("Fiscal ...

Organigram Holdings Inc. (NASDAQ:OGI) Q3 2024 Earnings Conference Call December 18, 2024 8:00 AM ET Company Participants Max Schwartz - Director of IR Beena Goldenberg - CEO Tim Emberg - CCO Greg Guyatt - CFO Conference Call Participants Aaron Grey - Alliance Global Partners Frederico Gomes - ATB Capital Markets Pablo Zuanic - Zuanic & Associates Yewon Kang - Canaccord Genuity Operator Good morning. My name is Rob, and I will be your conference operator today. At this time, I would like to welcome everyone ...

Alan Brochstein, CFA, is one of the first investment professionals to focus exclusively on the cannabis industry. Alan got his start as a financial professional in the securities industry in 1986, managing investments in institutional environments until he founded AB Analytical Services in 2007 in order to provide independent consulting to registered investment advisors. He is also the managing partner of New Cannabis Ventures, a leading provider of relevant financial information in the cannabis industry si ...

Darren415 I last wrote about Organigram (NASDAQ:OGI) here almost three months ago, calling it a great deal. The stock has increased a lot since then, rising from $1.525 to $1.86, a gain of 22%, but I still like it a lot despite outpacing the market. The New Cannabis Ventures Global Cannabis Stock Index has declined 1% since that article, and the Canadian Cannabis LP Index has dropped to a record low, falling 12%. Organigram represents 12.2% of my Beat the Global Cannabis Stock Index model portfolio that I s ...

nathanphoto/iStock via Getty Images Organigram Holdings (NASDAQ:OGI) reported Q3-2024 results Tuesday morning, which showed improvement in revenues and net loss. The company's stock has been up 33% over the last twelve months. The company holds a lead position in the Canadian cannabis markets and reported increasing revenues for Q3 from cannabis sales. The company does not have a current US entry strategy, but its international exports of cannabis flower are increasing. The company's stock price is currentl ...

Group 1 - Organigram reported C$41.06 million in revenue for its fiscal third quarter, exceeding Wall Street's expectation of C$39.24 million, representing a 25% year-over-year increase from C$32.8 million [1][2] - The revenue increase is primarily attributed to higher recreational cannabis sales and the expansion of international supply agreements [2][3] - The company highlighted a significant improvement in adjusted EBITDA and strategic investments, particularly in the European market through its investment in Sanity Group [3] Group 2 - Following the positive earnings report, Organigram's stock rose by 25.4%, with trading volume exceeding 2.4 million shares, significantly above its daily average of approximately 695,000 shares [3][4]

Organigram Holdings Inc. (NASDAQ:OGI) Q3 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Max Schwartz - Director of Investor Relations Beena Goldenberg - Chief Executive Officer Greg Guyatt - Chief Financial Officer Conference Call Participants Aaron Grey - AGP Pablo Zuanic - Zuanic & Associates Frederico Gomes - ATB Capital Markets Yewon Kang - Canaccord Genuity Operator Good morning. My name is Keyla, and I'll be your conference operator today. At this time, I would like to w ...